1887
  1. Home
  2. Eurosurveillance
  3. Volume 31, Issue 15, 16/Apr/2026
  4. Article
Research Open Access
Like 0
Download

2025 theme: Vaccines

Abstract

BACKGROUND

Pneumococcal conjugate vaccines (PCVs) have reduced vaccine-type (VT) invasive pneumococcal disease (IPD) in older adults through direct and indirect effects. However, non-vaccine-type serotypes have emerged. Since the recently licensed PCV20 and PCV21 vaccines differ in serotype composition, epidemiological data are essential to guide adult vaccination policy.

AIM

We aimed to assess serotype-specific IPD dynamics in older adults in Israel and evaluate the potential impact of implementing either the PCV20 or PCV21 vaccine in the adult National Immunisation Programme (NIP).

METHODS

In a national active IPD surveillance study in Israel, 2009–2024, on adults aged ≥ 65 years, IPD incidence per 100,000 population was assessed by age group, individual serotype and VT group.

RESULTS

We recorded 3,553 IPD episodes. All-IPD incidence was relatively stable between 2014/15 and 2023/24, excluding the COVID-19 period. In the late PCV13 period (2014–2019, 1,210 IPD episodes) and late/post COVID-19 pandemic (2021-2024, 608 episodes) periods, incidence of serotypes unique to PCV21 (VT21-only) was consistently higher than that of those unique to PCV20 (VT20-only). During 2022–2024, VT21-only IPD constituted 25.5% of all-IPD cases compared with 10.9% for VT20-only. Of the VT20-only serotypes, serotype 14 showed the highest late/post-pandemic incidence (1.76 per 100,000).

CONCLUSIONS

The PCV21 vaccine currently demonstrates broader serotype coverage than PCV20 among older adults in Israel. However, the spectrum of serotypes only partially overlap. Potential further serotype-specific dynamics following PCV20 implementation in the paediatric NIP and unknown actual effectiveness of newly introduced vaccine serotypes make it difficult to accurately predict impact following implementation.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2026.31.15.2500589
2026-04-16
2026-05-15
/content/10.2807/1560-7917.ES.2026.31.15.2500589
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/31/15/eurosurv-31-15-4.html?itemId=/content/10.2807/1560-7917.ES.2026.31.15.2500589&mimeType=html&fmt=ahah

References

  1. Phillips MT, Warren JL, Givon-Lavi N, Tothpal A, Regev-Yochay G, Dagan R, et al. Evaluating post-vaccine expansion patterns of pneumococcal serotypes. Vaccine. 2020;38(49):7756-63.  https://doi.org/10.1016/j.vaccine.2020.10.045  PMID: 33164799 
  2. Bertran M, D’Aeth JC, Abdullahi F, Eletu S, Andrews NJ, Ramsay ME, et al. Invasive pneumococcal disease 3 years after introduction of a reduced 1 + 1 infant 13-valent pneumococcal conjugate vaccine immunisation schedule in England: a prospective national observational surveillance study. Lancet Infect Dis. 2024;24(5):546-56.  https://doi.org/10.1016/S1473-3099(23)00706-5  PMID: 38310905 
  3. Garcia Quesada M, Peterson ME, Bennett JC, Hayford K, Zeger SL, Yang Y, et al. Serotype distribution of remaining invasive pneumococcal disease after extensive use of ten-valent and 13-valent pneumococcal conjugate vaccines (the PSERENADE project): a global surveillance analysis. Lancet Infect Dis. 2025;25(4):445-56.  https://doi.org/10.1016/S1473-3099(24)00588-7  PMID: 39706205 
  4. Platt HL, Bruno C, Buntinx E, Pelayo E, Garcia-Huidobro D, Barranco-Santana EA, et al. Safety, tolerability, and immunogenicity of an adult pneumococcal conjugate vaccine, V116 (STRIDE-3): a randomised, double-blind, active comparator controlled, international phase 3 trial. Lancet Infect Dis. 2024;24(10):1141-50.  https://doi.org/10.1016/S1473-3099(24)00344-X  PMID: 38964361 
  5. Ben-Shimol S, Regev-Yochay G, Givon-Lavi N, van der Beek BA, Brosh-Nissimov T, Peretz A, et al. Dynamics of invasive pneumococcal disease in Israel in children and adults in the 13-Valent pneumococcal conjugate vaccine (PCV13) era: A nationwide prospective surveillance. Clin Infect Dis. 2022;74(9):1639-49.  https://doi.org/10.1093/cid/ciab645  PMID: 34293091 
  6. Regev-Yochay G, Katzir M, Strahilevitz J, Rahav G, Finn T, Miron D, et al. The herd effects of infant PCV7/PCV13 sequential implementation on adult invasive pneumococcal disease, six years post implementation; a nationwide study in Israel. Vaccine. 2017;35(18):2449-56.  https://doi.org/10.1016/j.vaccine.2017.03.031  PMID: 28342668 
  7. U.S. Food and Drug Administration. CAPVAXIVE: Pneumococcal 21-valent Conjugate Vaccine. Silver Spring: U.S. Food and Drug Administration. [Accessed: 12 Apr 2025]. Available from: https://www.fda.gov/vaccines-blood-biologics/capvaxive
  8. U.S. Food and Drug Administration. PREVNAR 20: Pneumococcal 20-valent Conjugate Vaccine. Silver Spring: U.S. Food and Drug Administration. [Accessed: 12 Apr 2025]. Available from: https://www.fda.gov/vaccines-blood-biologics/prevnar-20-pneumococcal-20-valent-conjugate-vaccine
  9. Kobayashi M, Leidner AJ, Gierke R, Xing W, Accorsi E, Moro P, et al. Expanded recommendations for use of pneumococcal conjugate vaccines among adults aged ≥50 years: recommendations of the Advisory Committee on Immunization Practices — United States, 2024. MMWR Morb Mortal Wkly Rep. 2025;74(1):1-8.  https://doi.org/10.15585/mmwr.mm7401a1  PMID: 39773952 
  10. Ben-Shimol S, Greenberg D, Givon-Lavi N, Schlesinger Y, Somekh E, Aviner S, et al. Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance. Vaccine. 2014;32(27):3452-9.  https://doi.org/10.1016/j.vaccine.2014.03.065  PMID: 24690148 
  11. The Central Bureau of Statistics (CBS). Homepage. Jerusalem: CBS. [Accessed: 12 Apr 2025]. Available from: https://www.cbs.gov.il/en/Pages/default.aspx
  12. Ben-Shimol S, Greenberg D, Givon-Lavi N, Elias N, Glikman D, Rubinstein U, et al. Rapid reduction in invasive pneumococcal disease after introduction of PCV7 into the National Immunization Plan in Israel. Vaccine. 2012;30(46):6600-7.  https://doi.org/10.1016/j.vaccine.2012.08.012  PMID: 22939907 
  13. Regev-Yochay G, Reisenberg K, Katzir M, Wiener-Well Y, Rahav G, Strahilevitz J, et al. Pneumococcal meningitis in adults after introduction of PCV7 and PCV13, Israel, July 2009-June 20151. Emerg Infect Dis. 2018;24(7):1275-84.  https://doi.org/10.3201/eid2407.170721  PMID: 29912694 
  14. Bryant KA, Block SL, Baker SA, Gruber WC, Scott DA, PCV13 Infant Study Group. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine. Pediatrics. 2010;125(5):866-75.  https://doi.org/10.1542/peds.2009-1405  PMID: 20435707 
  15. Grant LR, O’Brien SE, Burbidge P, Haston M, Zancolli M, Cowell L, et al. Comparative immunogenicity of 7 and 13-valent pneumococcal conjugate vaccines and the development of functional antibodies to cross-reactive serotypes. PLoS One. 2013;8(9):e74906.  https://doi.org/10.1371/journal.pone.0074906  PMID: 24086394 
  16. Essink B, Sabharwal C, Cannon K, Frenck R, Lal H, Xu X, et al. Pivotal Phase 3 randomized clinical trial of the safety, tolerability, and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults aged ≥18 years. Clin Infect Dis. 2022;75(3):390-8.  https://doi.org/10.1093/cid/ciab990  PMID: 34940806 
  17. Cuypers L, Dambre C, Desmet S. Exceptional high number of IPD cases in winter season 2024-2025 in Belgium in concomitance with rise in vaccine serotypes. Vaccine. 2025;64:127763.  https://doi.org/10.1016/j.vaccine.2025.127763  PMID: 40966978 
  18. Tiley KS, Ratcliffe H, Voysey M, Jefferies K, Sinclair G, Carr M, et al. Nasopharyngeal carriage of pneumococcus in children in England up to 10 years after 13-valent pneumococcal conjugate vaccine introduction: persistence of serotypes 3 and 19A and emergence of 7C. J Infect Dis. 2023;227(5):610-21.  https://doi.org/10.1093/infdis/jiac376  PMID: 36130327 
  19. Yildirim I, Lapidot R, Shaik-Dasthagirisaheb YB, Hinderstein S, Lee H, Klevens M, et al. Invasive pneumococcal disease after 2 decades of pneumococcal conjugate vaccine use. Pediatrics. 2024;153(1):e2023063039.  https://doi.org/10.1542/peds.2023-063039  PMID: 38087952 
  20. Usuf E, Bottomley C, Gladstone R, Bojang E, Jawneh K, Cox I, et al. Persistent and emerging pneumococcal carriage serotypes in a rural Gambian community after 10 years of pneumococcal conjugate vaccine pressure. Clin Infect Dis. 2021;73(11):e3825-35.  https://doi.org/10.1093/cid/ciaa856  PMID: 32584973 
  21. Kobayashi M, Leidner AJ, Gierke R, Farrar JL, Morgan RL, Campos-Outcalt D, et al. Use of 21-Valent pneumococcal conjugate vaccine among U.s. adults: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024. MMWR Morb Mortal Wkly Rep. 2024;73(36):793-8.  https://doi.org/10.15585/mmwr.mm7336a3  PMID: 39264843 
  22. Pérez-García C, Sempere J, de Miguel S, Hita S, Úbeda A, Vidal EJ, et al. Surveillance of invasive pneumococcal disease in Spain exploring the impact of the COVID-19 pandemic (2019-2023). J Infect. 2024;89(2):106204.  https://doi.org/10.1016/j.jinf.2024.106204  PMID: 38906265 
  23. Beall B, Walker H, Tran T, Li Z, Varghese J, McGee L, et al. Upsurge of conjugate vaccine serotype 4 invasive pneumococcal disease clusters among adults experiencing homelessness in California, Colorado, and New Mexico. J Infect Dis. 2021;223(7):1241-9.  https://doi.org/10.1093/infdis/jiaa501  PMID: 32798216 
  24. Wieder-Finesod A, Yahav D, Rubin C, Hashkor S, Southern J, Mircus G, et al. Case-fatality rate of invasive pneumococcal disease caused by various serotypes-an analysis of nationwide surveillance data from Israel, 2009-2018. Clin Microbiol Infect. 2025;31(2):226-32.  https://doi.org/10.1016/j.cmi.2024.11.018  PMID: 39551343 
  25. Méroc E, Fletcher MA, Hanquet G, Slack MPE, Baay M, Hayford K, et al. Systematic literature review of the epidemiological characteristics of pneumococcal disease caused by the additional serotypes covered by the 20-valent pneumococcal conjugate vaccine. Microorganisms. 2023;11(7):1816.  https://doi.org/10.3390/microorganisms11071816  PMID: 37512988 
  26. Schellenberg JJ, Adam HJ, Baxter MR, Karlowsky JA, Golden AR, Martin I, et al. Comparison of PCV10, PCV13, PCV15, PCV20 and PPSV23 vaccine coverage of invasive Streptococcus pneumoniae isolate serotypes in Canada: the SAVE study, 2011-20. J Antimicrob Chemother. 2023;78(Suppl 1):i37-47.  https://doi.org/10.1093/jac/dkad068  PMID: 37130588 
  27. King LM, Andrejko KL, Kobayashi M, Xing W, Cohen AL, Self WH, et al. Pneumococcal serotype distribution and coverage of existing and pipeline pneumococcal vaccines. J Infect Dis. 2025;232(4):e609-20.  https://doi.org/10.1093/infdis/jiaf376  PMID: 40692487 
Anticipating impact of implementing PCV20 or PCV21 vaccines for older adults in the immunisation programme for invasive pneumococcal disease, using nationwide surveillance data, Israel, 2009 to 2024
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Romy+Rieger&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Rieger Romy</a>, <a href="/search?value1=Dafna+Yahav&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Yahav Dafna</a>, <a href="/search?value1=Ili+Margalit&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Margalit Ili</a>, <a href="/search?value1=Anat+Wieder-Finesod&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Wieder-Finesod Anat</a>, <a href="/search?value1=Hovav+Azulay&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Azulay Hovav</a>, <a href="/search?value1=Nesrin+Ghanem-Zoubi&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Ghanem-Zoubi Nesrin</a>, <a href="/search?value1=Alaa+Atamna&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Atamna Alaa</a>, <a href="/search?value1=Yehudit+Schindler&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Schindler Yehudit</a>, <a href="/search?value1=Hiba+Abu+Zayyad&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Abu Zayyad Hiba</a>, <a href="/search?value1=Ron+Dagan&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Dagan Ron</a>, <a href="/search?value1=Gili+Regev-Yochay&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Regev-Yochay Gili</a>, <a href="/search?value1=on+behalf+of+the+Israeli+Adult+Pneumococcal+Invasive+Disease+%28IAIPD%29+group&option1=author&noRedirect=true" class="nonDisambigAuthorLink">on behalf of the Israeli Adult Pneumococcal Invasive Disease (IAIPD) group</a></span>. Anticipating impact of implementing PCV20 or PCV21 vaccines for older adults in the immunisation programme for invasive pneumococcal disease, using nationwide surveillance data, Israel, 2009 to 2024. <a href="/content/ecdc">Euro Surveill.</a> 2026;31(15):pii=2500589. <a href="https://doi.org/10.2807/1560-7917.ES.2026.31.15.2500589" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2026.31.15.2500589</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 05 Aug 2025;&nbsp;&nbsp; <span class="generated">Accepted</span>: 08 Dec 2025 </span> </p>
/content/10.2807/1560-7917.ES.2026.31.15.2500589
/content/10.2807/1560-7917.ES.2026.31.15.2500589
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error